Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.

Abstract	Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in patients with locally advanced/MBC, irrespective of the location of metastases at baseline. A nominally significant difference in OS in favor of patients randomized to eribulin compared with control in patients with bone, lymph node, and chest wall/breast/skin metastases at baseline was observed. Additionally, a difference in OS was also seen in patients with liver metastases randomized to eribulin versus control (median: 13.4 versus 11.3 months, respectively; hazard ratio, 0.84 [95% CI: 0.72, 0.97]). Results of this exploratory analysis suggest that eribulin may be efficacious for the treatment of locally advanced/MBC for patients with bone, liver, lung, lymph node, and chest wall/breast/skin metastases.
Authors	Joyce O'Shaughnessy, Javier Cortes, Chris Twelves, Lori J Goldstein, Karenza Alexis, Ran Xie, Carlos Barrios, Takayuki Ueno
Journal	Scientific reports (Sci Rep) Vol. 10 Issue 1 Pg. 11203 (07 08 2020) ISSN: 2045-2322 [Electronic] England
PMID	32641747 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antineoplastic Agents Furans Ketones eribulin
Topics	Adult Antineoplastic Agents (therapeutic use) Bone and Bones (pathology) Breast (pathology) Breast Neoplasms (drug therapy, mortality, pathology) Clinical Trials, Phase III as Topic Female Follow-Up Studies Furans (therapeutic use) Humans Ketones (therapeutic use) Liver (pathology) Lung (pathology) Lymph Nodes (pathology) Middle Aged Multicenter Studies as Topic Neoplasm Metastasis (drug therapy) Prognosis Progression-Free Survival Randomized Controlled Trials as Topic Risk Factors Skin (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!